We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medical Product Stocks' Earnings on Jul 20: ABT, ISRG & More
Read MoreHide Full Article
The second-quarter earnings season is in its nascent stage with 30 S&P 500 participants having reported results as of Jul 14. According to the latest Earnings Preview, the earnings cycle has witnessed an encouraging start, courtesy of stable bank results. Total earnings for these members have gone up 13.8% on 6.0% increase in revenues. The uptrend was the result of reduced regulatory burden, tax law changes and an improved outlook for the domestic economy.
Per the latest Earnings Preview report, the second-quarter earnings for the S&P 500 companies are expected to be up 6.6% from the year-ago quarter on 4.5% higher revenues. With the majority of earnings yet to be released, the next fortnight will be crucial in deciding whether this quarter will turn out to be a game changer. Irrespective of the outcome, investors focusing on the Medical sector can expect good news.
The medical sector, one of the 16 broader Zacks sectors, is expected to witness 3.7% higher revenues in the quarter along with a decline of 1.0% in revenues. Investors are adopting a wait and watch about the space as the Zacks categorized Medical - Products industry has registered growth of 0.55% in the last one month, underperforming the S&P 500 Index that gained around 0.86%. The market remained jittery for a major part of the month due to uncertainties surrounding the future of the healthcare act.
Let’s take a sneak peek into the performance of four major medical product companies that are expected to report earnings early next week.
Abbott Laboratories (ABT - Free Report) is scheduled to report second-quarter 2017 results before the opening bell on Jul 20. Abbott has been on a healthy growth trajectory in Established Pharmaceuticals Division (EPD) business. The company has delivered encouraging operational sales growth in the trailing few quarters. However, the absence of any substantial advancement in this division in the recent past has compelled the company to maintain low expectations at high single-digit growth in the yet-to-be reported quarter. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Our proven model does not conclusively show that Abbott is likely to beat earnings this quarter. This is because Abbott Laboratories has an Earnings ESP of 0.00% and a Zacks Rank #2 (Buy). That is because both the Most Accurate estimate and the Zacks Consensus Estimate are at 60 cents. Abbott’s Zacks Rank #2 increases the predictive power of ESP. However, the company’s 0.00% ESP makes surprise prediction difficult. (Read more: Can Abbott Laboratories Pull a Surprise in Q2 Earnings?)
Intuitive Surgical Inc. (ISRG - Free Report) is set to report second-quarter results after the closing bell. We believe that growing adoption of Intuitive Surgical’s da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a key growth catalyst for the company. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Our proven model does not conclusively show that Intuitive Surgical is likely to beat on earnings this quarter. This is because Intuitive Surgical currently has an Earnings ESP of 0.00% and a Zacks Rank #3 (Hold). This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at $4.86. (Read more: Will Intuitive Surgical Surprise in Q2 Earnings?).
Headquartered in Watertown, MA, athenahealth Inc. , through its cloud-based network provides services that manage the administrative duties of medical providers. The company’s software platform handles billing management, quality measurement and reporting, clinical documentation and data exchange, patient communication and referrals and many other related tasks.
The company is scheduled to report second-quarter earnings. We believe that the company’s strong product portfolio, expanding physician base and unique business model will boost prospects for the company. However, our proven model does not conclusively show that the company is likely to beat on earnings, given the combination of a Zacks Rank #3 and Earnings ESP of 0.00%. (Read more: What's in Store for athenahealth in Q2 Earnings?).
Abaxis, Inc. is scheduled to report its second-quarter 2017. It is a California-based manufacturer of portable Medical (human) and Veterinary (animal) blood analysis systems that provide clinicians with rapid blood constituent measurements in medical and veterinarian markets worldwide.
Abaxis currently carries a Zacks Rank #3 (Hold) and has an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 32 cents.
Irrespective of an earnings beat or miss, investors should focus on companies’ fundamentals to make investment decisions. Therefore, don’t forget to check our full write-up on earnings releases of these stocks later.
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medical Product Stocks' Earnings on Jul 20: ABT, ISRG & More
The second-quarter earnings season is in its nascent stage with 30 S&P 500 participants having reported results as of Jul 14. According to the latest Earnings Preview, the earnings cycle has witnessed an encouraging start, courtesy of stable bank results. Total earnings for these members have gone up 13.8% on 6.0% increase in revenues. The uptrend was the result of reduced regulatory burden, tax law changes and an improved outlook for the domestic economy.
Per the latest Earnings Preview report, the second-quarter earnings for the S&P 500 companies are expected to be up 6.6% from the year-ago quarter on 4.5% higher revenues. With the majority of earnings yet to be released, the next fortnight will be crucial in deciding whether this quarter will turn out to be a game changer. Irrespective of the outcome, investors focusing on the Medical sector can expect good news.
The medical sector, one of the 16 broader Zacks sectors, is expected to witness 3.7% higher revenues in the quarter along with a decline of 1.0% in revenues. Investors are adopting a wait and watch about the space as the Zacks categorized Medical - Products industry has registered growth of 0.55% in the last one month, underperforming the S&P 500 Index that gained around 0.86%. The market remained jittery for a major part of the month due to uncertainties surrounding the future of the healthcare act.
Let’s take a sneak peek into the performance of four major medical product companies that are expected to report earnings early next week.
Abbott Laboratories (ABT - Free Report) is scheduled to report second-quarter 2017 results before the opening bell on Jul 20. Abbott has been on a healthy growth trajectory in Established Pharmaceuticals Division (EPD) business. The company has delivered encouraging operational sales growth in the trailing few quarters. However, the absence of any substantial advancement in this division in the recent past has compelled the company to maintain low expectations at high single-digit growth in the yet-to-be reported quarter. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Our proven model does not conclusively show that Abbott is likely to beat earnings this quarter. This is because Abbott Laboratories has an Earnings ESP of 0.00% and a Zacks Rank #2 (Buy). That is because both the Most Accurate estimate and the Zacks Consensus Estimate are at 60 cents. Abbott’s Zacks Rank #2 increases the predictive power of ESP. However, the company’s 0.00% ESP makes surprise prediction difficult. (Read more: Can Abbott Laboratories Pull a Surprise in Q2 Earnings?)
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
Intuitive Surgical Inc. (ISRG - Free Report) is set to report second-quarter results after the closing bell. We believe that growing adoption of Intuitive Surgical’s da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a key growth catalyst for the company. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Our proven model does not conclusively show that Intuitive Surgical is likely to beat on earnings this quarter. This is because Intuitive Surgical currently has an Earnings ESP of 0.00% and a Zacks Rank #3 (Hold). This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at $4.86. (Read more: Will Intuitive Surgical Surprise in Q2 Earnings?).
Intuitive Surgical, Inc. Price and EPS Surprise
Intuitive Surgical, Inc. Price and EPS Surprise | Intuitive Surgical, Inc. Quote
Headquartered in Watertown, MA, athenahealth Inc. , through its cloud-based network provides services that manage the administrative duties of medical providers. The company’s software platform handles billing management, quality measurement and reporting, clinical documentation and data exchange, patient communication and referrals and many other related tasks.
The company is scheduled to report second-quarter earnings. We believe that the company’s strong product portfolio, expanding physician base and unique business model will boost prospects for the company. However, our proven model does not conclusively show that the company is likely to beat on earnings, given the combination of a Zacks Rank #3 and Earnings ESP of 0.00%. (Read more: What's in Store for athenahealth in Q2 Earnings?).
athenahealth, Inc. Price and EPS Surprise
athenahealth, Inc. Price and EPS Surprise | athenahealth, Inc. Quote
Abaxis, Inc. is scheduled to report its second-quarter 2017. It is a California-based manufacturer of portable Medical (human) and Veterinary (animal) blood analysis systems that provide clinicians with rapid blood constituent measurements in medical and veterinarian markets worldwide.
Abaxis currently carries a Zacks Rank #3 (Hold) and has an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 32 cents.
ABAXIS, Inc. Price and EPS Surprise
ABAXIS, Inc. Price and EPS Surprise | ABAXIS, Inc. Quote
Irrespective of an earnings beat or miss, investors should focus on companies’ fundamentals to make investment decisions. Therefore, don’t forget to check our full write-up on earnings releases of these stocks later.
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>